Alyssa M. Peckham, Pharm.D., BCPP

Assistant Professor

Midwestern University

College of Pharmacy
Department of Pharmacy Practice
Cholla Hall, Office 201-1

19555 N 59th Ave
Glendale, AZ 85308

Office: (623) 572-3526


Doctor of Pharmacy University of Rhode Island 2014
Board Certified Psychiatric Pharmacist Board of Pharmacy Specialties 2016


Substance abuse and other psychiatric disorders

I am primarily interested in prevalence of substance abuse, current treatment modalities, and economic, humanistic, and medical consequences of substance abuse. In addition, I am interested in the pharmacoeconomics of various psychiatric disorders, as well as new mechanistic pathways targeting mental illness pathophysiology.

Research projects

Naloxone: Expanding upon prior to naloxone research to (1) survey medication providers to assess any discernible barriers to program implementation (2) survey naloxone recipients regarding knowledge of naloxone and opioid overdose to assess program impact and (3) assess time to program implementation as it relates to state-specific naloxone legislature.

Gabapentin: Conducting the first large-sample study to report prevalence of gabapentin abuse as it compares to agents of known abuse potential.

ADHD: Currently assessing degree of cardiovascular risk and outcomes in those that are prescribed stimulants for the treatment of ADHD.

Selected Publications

  1. Fairman KA, Peckham AM, Sclar DA. Diagnosis and Treatment of ADHD in the United States. J Atten Disord. 2017 Feb 1:1087054716688534. doi: 10.1177/1087054716688534. [Epub ahead of print]
  2. Peckham AM, Boggs, DL. The Overdose Education and Naloxone Distribution Program at a VA Hospital. Fed Pract. Nov 2016;33(11):28-31.
  3. Boggs, DL, Peckham A, Boggs AA, Ranganathan M. Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the ''weed,'' a pharmacodynamic discussion. Ment Health Clin [Internet]. Nov 2016;6(6):277-84. DOI: 10.9740/mhc.2016.11.277.